載入中
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
前收盤價
US$2.45
+US$0.08 · +3.38%
盤中時間採用ET。市場資料可能有所延遲。
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
日內區間
目前US$2.45
52週區間
目前US$2.45
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
47
合理估值
情緒
44
多空交錯
風險
62
高風險
動能
34
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
日內區間
目前US$2.45
52週區間
目前US$2.45
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 4037.4萬 USD | 8000.1萬 USD | 2.5億 USD | 4090.7萬 USD | 3741.5萬 USD |
| 銷貨成本 | 1.32億 USD | — | 9217.2萬 USD | 5576.4萬 USD | 7378.7萬 USD |
| 毛利 | −9190萬 USD | 8000.1萬 USD | 1.58億 USD | −1485.7萬 USD | −3637.2萬 USD |
| 研究與開發 | 1.35億 USD | 1.27億 USD | 9217.2萬 USD | 6076.4萬 USD | 7378.7萬 USD |
| 銷售、一般及管理費用 | 3644.4萬 USD | 3592萬 USD | 3582.2萬 USD | 3098萬 USD | 3724.6萬 USD |
| 營業費用 | 3994.4萬 USD | 1.63億 USD | 3582.2萬 USD | 3598萬 USD | 3724.6萬 USD |
| 利息收入 | 1061.8萬 USD | 1832.8萬 USD | 1172.1萬 USD | 179.2萬 USD | — |
| 折舊和攤銷 | 406萬 USD | 473.1萬 USD | 444.1萬 USD | 619.1萬 USD | 516.5萬 USD |
| 營業利益 | −1.32億 USD | −8328.7萬 USD | 1.22億 USD | −5083.7萬 USD | −7361.8萬 USD |
| 淨利 | −1.2億 USD | −6500.2萬 USD | 1.32億 USD | −4640.8萬 USD | −7119.7萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$14.40
上漲空間 487.76%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI576.8萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM333.26萬0.00%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF211.53萬0.00%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO104.38萬0.01%180億 USD0.06%US$112.66+0.50%
iShares Biotechnology ETFIBB90.59萬0.01%108.2億 USD0.44%US$206.49+3.00%
Dimensional - US Small Cap ETFDFAS69.56萬0.00%338.69億 USD0.31%US$78.35+0.32%
Fidelity Enhanced Small Cap ETFFESM39.54萬0.01%64.1億 USD0.28%US$45.46+0.46%
iShares Micro-Cap ETFIWC39.01萬0.03%13.17億 USD0.60%US$183+0.11%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASFidelity Enhanced Small Cap ETFFESMiShares Micro-Cap ETFIWCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
